CCM
AVIR icon

CAAS Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

CAAS Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-70,000
Closed -$2.92M – 1148
2020
Q4 		$2.92M Buy
+70,000
New +$2.26M 0.03% 422

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

CAAS Capital Management's AVIR Position: Q1 2021 in Review

CAAS Capital Management sold out of Atea Pharmaceuticals (AVIR) in Q1 2021, closing a stake of 70,000 shares — an estimated $2.92M sold.

CAAS Capital Management first reported a position in AVIR in Q4 2020 and held it in 1 quarter. The position peaked at $2.92M in Q4 2020. 81 funds tracked by Wall St. Rank hold AVIR as of Q1 2021.

  • CAAS Capital Management reported no remaining Atea Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • CAAS Capital Management sold 70,000 Atea Pharmaceuticals shares in Q1 2021, an estimated $2.92M.
  • CAAS Capital Management first reported a position in Atea Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • CAAS Capital Management's Atea Pharmaceuticals position peaked at $2.92M in Q4 2020.
  • 81 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2021.

Based on CAAS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.